Literature DB >> 8100197

The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat.

M Trampus1, N Ferri, M Adami, E Ongini.   

Abstract

The effects of the dopamine D1 receptor full agonist, A68930, on sleep-wake patterns and grooming behaviour were studied in the rat. The partial dopamine D1 receptor agonist, SKF 38393, was used for comparison. A68930 (0.003-0.3 mg/kg s.c.) increased waking time, reduced the amount of rapid eye movement (REM) sleep and enhanced spontaneous grooming dose dependently. The ED50 were 0.06, 0.02 and 0.05 mg/kg, respectively. The D1 antagonist, SCH 23390 (0.003 mg/kg s.c.), blocked the effects of A68930 on wakefulness and grooming but not those on REM sleep. SKF 38393 (0.1-10 mg/kg s.c.) increased grooming with an ED50 of 1.4 mg/kg and a dose-response relationship similar to that of A68930 (potency ratio 28). Conversely, the increase of wakefulness and reduction of REM sleep caused by SKF 38393 had dose-response curves different from those of A68930. The results support the view that D1 receptors may have a physiological function in producing arousal.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100197     DOI: 10.1016/0014-2999(93)90823-z

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Sleep onset insomnia, daytime sleepiness and sleep duration in relationship to Toxoplasma gondii IgG seropositivity and serointensity.

Authors:  Zaki Ahmad; Yara W Moustafa; John W Stiller; Mary A Pavlovich; Uttam K Raheja; Claudia Gragnoli; Soren Snitker; Sarra Nazem; Aline Dagdag; Beverly Fang; Dietmar Fuchs; Christopher A Lowry; Teodor T Postolache
Journal:  Pteridines       Date:  2017-11-28       Impact factor: 0.581

2.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

3.  Association Between Dopaminergic Medications and the Evolution of REM Sleep Behavior Disorder in Parkinson's Disease.

Authors:  Ruihua Cao; Ruolin Ma; Kai Wang; Panpan Hu
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

4.  Activation of D1 dopamine receptors induces emergence from isoflurane general anesthesia.

Authors:  Norman E Taylor; Jessica J Chemali; Emery N Brown; Ken Solt
Journal:  Anesthesiology       Date:  2013-01       Impact factor: 7.892

5.  Sleep and Wakefulness Are Controlled by Ventral Medial Midbrain/Pons GABAergic Neurons in Mice.

Authors:  Yohko Takata; Yo Oishi; Xu-Zhao Zhou; Emi Hasegawa; Koji Takahashi; Yoan Cherasse; Takeshi Sakurai; Michael Lazarus
Journal:  J Neurosci       Date:  2018-10-03       Impact factor: 6.167

6.  Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.

Authors:  Yan Wang; Yuechang Yang; Huijuan Wu; Danmei Lan; Ying Chen; Zhongxin Zhao
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

7.  The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.

Authors:  John A Gruner; Val R Marcy; Yin-Guo Lin; Donna Bozyczko-Coyne; Michael J Marino; Maciej Gasior
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

8.  Sleep-promoting properties of quetiapine in healthy subjects.

Authors:  Stefan Cohrs; Andrea Rodenbeck; Zhenghua Guan; Kathrin Pohlmann; Wolfgang Jordan; Andreas Meier; Eckart Rüther
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

9.  Neurotoxic N-methyl-D-aspartate lesion of the ventral midbrain and mesopontine junction alters sleep-wake organization.

Authors:  Y Y Lai; T Shalita; T Hajnik; J P Wu; J S Kuo; L G Chia; J M Siegel
Journal:  Neuroscience       Date:  1999-05       Impact factor: 3.590

Review 10.  Sleep disturbances, psychiatric disorders, and psychotropic drugs.

Authors:  Luc Staner
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.